title: Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
abstract: BACKGROUND
  The excision repair cross-complementation group 1 (ERCC1) codon 118 C/T polymorphism has been associated with clinical outcome in cancer patients treated with platinum chemotherapy. Ethnic differences in the frequency of this polymorphism have been observed in Caucasian and African populations.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the frequency and survival benefit of the ERCC1 codon 118 C/T polymorphism in a high-altitude population with advanced gastric cancer.
  
  
  METHODS
  Polymerase chain reaction-restriction fragment length polymorphism was used to determine the frequency of ERCC1 118 codon C/T polymorphism in 206 advanced gastric cancer patients residing in the high-altitude Qinghai-Tibetan plateau. The influence of the ERCC1 codon 118 C/T polymorphism on its micro ribonucleic acid (mRNA) and protein expression, clinicopathological features; response to the platinum-based combination chemotherapy, and the outcome was evaluated.
  
  
  METHODS
  The Kaplan-Meier method was used for survival analysis. The correlation of ERCC1 codon 118 polymorphism with ERCC1 mRNA and protein expression, clinicopathological characteristics, and first-line oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-4) response was determined by χ(2)-test.
  
  
  CONCLUSIONS
  ERCC1 codon 118 C/T polymorphism was not associated with ERCC1 mRNA and protein expression, FOLFOX-4 response, and progression-free survival (PFS) or overall survival (OS). High ERCC1 mRNA and protein expression levels were associated with significantly lower FOLFOX-4 responses, PFS, and OS. ERCC1 codon 118 C/T polymorphism is not an important prognostic marker for advanced gastric cancer. Determination of ERCC1 mRNA and protein levels may be beneficial in predicting the response and outcome of FOLFOX-4 therapy in gastric cancer.
authors.affiliation: Research Center for High Altitude Medicine, Qinghai University School of Medicine, Xining 810001, Qinghai, China.
authors.forename: Yu-Juan
authors.initials: YJ
authors.lastname: Qi
authors.forename: Sen
authors.initials: S
authors.lastname: Cui
authors.forename: Ying-Zhong
authors.initials: YZ
authors.lastname: Yang
authors.forename: Jing-Qi
authors.initials: JQ
authors.lastname: Han
authors.forename: Bao-Jia
authors.initials: BJ
authors.lastname: Cai
authors.forename: Cun-Fang
authors.initials: CF
authors.lastname: Sheng
authors.forename: Yan
authors.initials: Y
authors.lastname: Ma
authors.forename: Tana
authors.initials: T
authors.lastname: Wuren
authors.forename: Ri-Li
authors.initials: RL
authors.lastname: Ge
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002681:China / Q000208:ethnology; D003062:Codon; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D004720:Endonucleases / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D017422:Sequence Analysis, DNA; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D003062:Codon; D004268:DNA-Binding Proteins; D035683:MicroRNAs; D009944:Organoplatinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases; D002955:Leucovorin; D005472:Fluorouracil